tiagabine has been researched along with carbachol in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bruno-Blanch, L; Gálvez, J; García-Domenech, R | 1 |
| Cull-Candy, SG; Dupree, JL; Edwards, J; Farrant, M; Gallo, V; Harvey, L; Hübner, CA; Li, P; McEllin, B; Scafidi, J; Sun, D; Zonouzi, M | 1 |
2 other study(ies) available for tiagabine and carbachol
| Article | Year |
|---|---|
Topological virtual screening: a way to find new anticonvulsant drugs from chemical diversity.
Topics: Anticonvulsants; Computer Simulation; Databases, Factual; Discriminant Analysis; Drug Design; Molecular Structure; Quantitative Structure-Activity Relationship | 2003 |
GABAergic regulation of cerebellar NG2 cell development is altered in perinatal white matter injury.
Topics: Action Potentials; Animals; Animals, Newborn; Asphyxia Neonatorum; Carbachol; Cell Count; Cells, Cultured; Cerebellum; Demyelinating Diseases; Disease Models, Animal; Female; GABA-A Receptor Antagonists; gamma-Aminobutyric Acid; Hypoxia, Brain; Interneurons; Male; Mice; Mice, Knockout; Mice, Transgenic; Neural Stem Cells; Neurogenesis; Nipecotic Acids; Oligodendroglia; Purkinje Cells; Receptors, GABA-A; Solute Carrier Family 12, Member 2; Tiagabine; Vigabatrin; White Matter | 2015 |